Category Archives: HIV/AIDS

What We’re Reading: Why it’s time to pick the next PEPFAR leader

By on .

Leader Needed to Fight Another Pandemic: HIV – While the COVID-19 pandemic has disrupted HIV services worldwide, the office of U.S. Global AIDS Coordinator has remained vacant since January. This vacancy at the helm of this country’s flagship response to the HIV pandemic “calls into question our commitment to the humanitarian vision and recognition of […]

Virtual CROI 2021: Disparate impacts of two pandemics highlight systemic and leadership failures across four decades

By on .

As the AIDS epidemic emerged and spread in 1981, its swift and steep death toll raising urgent needs for answers and action, it was met at first with silence, a speaker at today’s virtual CROI noted. President Reagan did not acknowledge the pandemic or say the word AIDS until 1987, while other officials spoke of […]

Virtual CROI 2021: In opening talk Dr. Fauci looks at the “two-way street” of lessons from HIV and COVID-19

By on .

Transmitted by people without symptoms, hitting populations regarded too widely as “disposable,” its spread facilitated by claims the deadly public health threat is a hoax, and presenting lessons in research that include the critical roles of community engagement and of collaborative endeavors reaching across disciplines and national boundaries, HIV offered valuable lessons to scientists and […]

Lancet series highlights a vicious circle of inequities hobbling efforts to end disease spread

By on .

Steeped in inequities that include formidable barriers to basic health services for multitudes of its most vulnerable, marginalized and neglected people, the country leading global HIV responses, continues to fall far short of attainable goals to control its epidemic at home, a Lancet series of articles by leading HIV researchers released today shows. While the […]

COVID vaccines in HIV-Positive recipients: Need for more data from the Novavax South Africa study and with other vaccine platforms

By on .

By Daniel R. Lucey MD, MPH, FIDSA The Jan. 28 Novavax press release that included preliminary results from its COVID-19 vaccine Phase 2b trial in South Africa appears to contain a significant difference in efficacy between volunteers who were HIV-positive and HIV-negative. If verified, then the implications warrant sustained attention for this protein-based adjuvanted COVID-19 […]

First long-acting injectable treatment for HIV represents an exciting step forward, should be optimized with equity, investment

By on .

First long-acting injectable treatment for HIV represents an exciting step forward, should be optimized with equity, investment Dr. Rajesh Gandhi is the Co-Director of the Harvard Center for AIDS Research and the site leader of the MGH Clinical Research Site in the Harvard/Miriam AIDS Clinical Trials Unit and a scientific member of the Department of […]

How do I know which adolescent girls are at greatest risk for HIV?

By on .

Innovative approaches can help find vulnerable young women in need of HIV prevention services The following is a guest post by Michelle Li, MS, and Quinn Lewis, MIA, of Data.FI project In sub-Saharan Africa, adolescent girls and young women are disproportionately impacted by HIV and are more likely to become infected, compared to their male […]

It’s a puzzle, it’s an algorithm, it’s deduplication

By on .

The following is a guest post by Richard Ngethe, MBA,  and Jonathan Friedman, MS According to a study by UNAIDS of Brazil, of an estimated 140 million records in the national user database—including all health records—only 100 million unique patients were represented. The number of patients, therefore, was overstated by 40%.[1] This is the kind […]

Four recommendations can move Indonesia toward achieving HIV epidemic control

By on .

The following is a guest post by Cathy Cantelmo, Rebecca Ross, Shree Prabhakaran and Arin Dutta Indonesia has not yet achieved UNAIDS 90-90-90 HIV treatment targets or epidemic control. Of the people living with HIV as of June 2020, only 63 percent knew their status, just a quarter were on antiretroviral therapy, and a mere […]